Zentalis Pharmaceuticals (ZNTL) Return on Sales (2024 - 2025)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Return on Sales of 0.06% for Q3 2025, down 1.0% year-over-year from 0.06% in Q3 2024, and up 8.27% quarter-over-quarter from 0.06% in Q2 2025.
Zentalis Pharmaceuticals (ZNTL) Return on Sales (2024 - 2025) Analysis & Trends
Zentalis Pharmaceuticals' Return on Sales history runs 2 years deep, the most recent figure standing at 0.06% for Q3 2025.
- In Q3 2025, Return on Sales fell 1.0% year-over-year to 0.06%; the TTM figure through Sep 2025 stood at 0.06% (down 1.0% YoY), while the FY2024 annual figure was 0.02%, changed N/A from the prior year.
- Return on Sales for Q3 2025 stood at 0.06%, up from 0.06% in the prior quarter.
- The five-year high for Return on Sales was 0.0% in Q1 2024, with the low at 0.08% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 0.00% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -0.06% |
| Jun 30, 2025 | -0.06% |
| Mar 31, 2025 | -0.08% |
| Dec 31, 2024 | -0.02% |
| Sep 30, 2024 | -0.04% |
| Jun 30, 2024 | -0.05% |
| Mar 31, 2024 | 0.00% |